132 results on '"Basnyat, Buddha"'
Search Results
2. Early Insights From Clinical Trials of Typhoid Conjugate Vaccine.
- Author
-
Neuzil, Kathleen M, Basnyat, Buddha, Clemens, John D, Gordon, Melita A, Patel, Priyanka D, Pollard, Andrew J, Shakya, Mila, and Qadri, Firdausi
- Subjects
- *
CLINICAL trials , *MEDICAL research , *TYPHOID fever , *TYPHOID vaccines , *TREATMENT effectiveness - Abstract
Clinical trials of typhoid conjugate vaccine (TCV) are ongoing in 4 countries. Early data confirm safety, tolerability, and immunogenicity of typhoid conjugate vaccine, and early efficacy results are promising. These data support World Health Organization recommendations and planned country introductions. Forthcoming trial data will continue to inform programmatic use of typhoid conjugate vaccine. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
3. A Review of Medical Problems in Himalayan Porters.
- Author
-
Dawadi, Suvash, Basnyat, Buddha, and Adhikari, Subarna
- Subjects
- *
MOUNTAIN sickness , *CEREBRAL edema , *PULMONARY edema , *MEDICAL literature , *ACUTE diseases - Abstract
Porters have accompanied trekkers and climbers to high altitude since the earliest expeditions in the Himalayas. As the existing body of knowledge on high-altitude medicine expands, the focus remains on trekkers or climbers. And published literature on medical problems in the large porter population remains sparse. It is well known that porters working at high altitude in the Nepal Himalayas are often lowland dwellers and are as prone to high-altitude illnesses such as acute mountain sickness, high-altitude pulmonary edema, and high-altitude cerebral edema as the trekkers are. Other illnesses such as diarrhea, respiratory illnesses, and infections also occur in this population. In this review, studies reporting these findings will be discussed along with the local context of socioeconomic barriers to adequate health care for these porters. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. Tuberculosis in South Asia: a tide in the affairs of men.
- Author
-
Basnyat, Buddha, Caws, Maxine, and Udwadia, Zarir
- Subjects
- *
TUBERCULOSIS mortality , *PUBLIC health , *MIXED infections , *MULTIDRUG-resistant tuberculosis , *HIV infections - Abstract
Background: Tuberculosis (TB) remains the most common cause of infectious disease deaths worldwide. What is perhaps less appreciated is that the caseload of tuberculosis patients in South Asia is staggering. South Asia has almost 40% of the global TB burden with 4,028,165 cases in 2015. This region also has a disproportionate share of TB deaths (681,975 deaths, 38% of the global burden). Worldwide just 12.5% of TB cases are in HIV positive individuals, but much research and investment has focused on HIV-associated TB. Only 3.5% of patients with tuberculosis in South Asia have HIV co-infection. Not surprisingly with such a huge burden of disease, this region has an estimated 184,336 multi drug resistant (MDR) cases among notified TB cases which accounts for a third of global MDR burden. Crucially, at least 70% of the estimated MDR cases remain untreated in this region and MDR treatment success ranged from only 46% for India to 88% for Sri Lanka in the 2012 cohort that received treatment. This region represents many of the drivers of the modern TB epidemic: rapid urbanization and high density populations with dramatically rising incidence of diabetes, a burgeoning and largely unregulated private sector with escalating drug resistance and high air pollution both outdoor and household. Conclusion: From bacterial biochemistry to policy implementation, we suggest ways in which South Asia can seize the opportunity lead global TB elimination by demonstrating feasibility in some of the world's most densely populated cities and remotest reaches of the Himalayas. Clearly political will is essential, but we cannot defeat TB without understanding how to eliminate it in South Asia. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
5. A 23-year retrospective investigation of Salmonella Typhi and Salmonella Paratyphi isolated in a tertiary Kathmandu hospital.
- Author
-
Zellweger, Raphaël M., Basnyat, Buddha, Shrestha, Poojan, Prajapati, Krishna G., Dongol, Sabina, Sharma, Paban K., Koirala, Samir, Darton, Thomas C., Dolecek, Christiane, Thompson, Corinne N., Thwaites, Guy E., Baker, Stephen G., and Karkey, Abhilasha
- Subjects
- *
SALMONELLA typhi , *DISEASE susceptibility , *ANTI-infective agents , *TYPHOID fever treatment , *RETROSPECTIVE studies - Abstract
Background: Salmonella serovars Typhi (S. Typhi) and Paratyphi A (S. Paratyphi A), the causative agents of enteric fever, have been routinely isolated organisms from the blood of febrile patients in the Kathmandu Valley since the early 1990s. Susceptibility against commonly used antimicrobials for treating enteric fever has gradually changed throughout South Asia since this time, posing serious treatment challenges. Here, we aimed to longitudinally describe trends in the isolation of Salmonella enterica and assess changes in their antimicrobial susceptibility in Kathmandu over a 23-year period. Methods: We conducted a retrospective analysis of standardised microbiological data from April 1992 to December 2014 at a single healthcare facility in Kathmandu, examining time trends of Salmonella-associated bacteraemia and the corresponding antimicrobial susceptibility profiles of the isolated organisms. Results: Over 23 years there were 30,353 positive blood cultures. Salmonella enterica accounted for 65.4% (19,857/30,353) of all the bacteria positive blood cultures. S. Typhi and S. Paratyphi A were the dominant serovars, constituting 68.5% (13,592/19,857) and 30.5% (6,057/19,857) of all isolated Salmonellae. We observed (i) a peak in the number of Salmonella-positive cultures in 2002, a year of heavy rainfall and flooding in the Kathmandu Valley, followed by a decline toward pre-flood baseline by 2014, (ii) an increase in the proportion of S. Paratyphi in all Salmonella-positive cultures between 1992 and 2014, (iii) a decrease in the prevalence of MDR for both S. Typhi and S. Paratyphi, and (iv) a recent increase in fluoroquinolone non-susceptibility in both S. Typhi and S. Paratyphi isolates. Conclusions: Our work describes significant changes in the epidemiology of Salmonella enterica in the Kathmandu Valley during the last quarter of a century. We highlight the need to examine current treatment protocols for enteric fever and suggest a change from fluoroquinolone monotherapy to combination therapies of macrolides or cephalosporins along with older first-line antimicrobials that have regained their efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Co-trimoxazole versus azithromycin for the treatment of undifferentiated febrile illness in Nepal: study protocol for a randomized controlled trial.
- Author
-
Pokharel, Sunil, Basnyat, Buddha, Arjyal, Amit, Pathak Mahat, Saruna, Raj Kumar, K. C., Bhuju, Abhusani, Poudyal, Buddhi, Kestelyn, Evelyne, Shrestha, Ritu, Dung Nguyen Thi Phuong, Thapa, Rajkumar, Karki, Manan, Dongol, Sabina, Karkey, Abhilasha, Wolbers, Marcel, Baker, Stephen, Thwaites, Guy, Mahat, Saruna Pathak, Kc, Raj Kumar, and Phuong, Dung Nguyen Thi
- Subjects
- *
TYPHOID fever treatment , *CO-trimoxazole , *AZITHROMYCIN , *FLUOROQUINOLONES , *RANDOMIZED controlled trials , *DIAGNOSIS of fever , *ANTIBIOTICS , *CLINICAL trials , *COMPARATIVE studies , *DRUG resistance in microorganisms , *EXPERIMENTAL design , *FEVER , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH protocols , *ORAL drug administration , *RESEARCH , *RESEARCH funding , *TIME , *TYPHOID fever , *EVALUATION research , *TYPHUS fever , *TREATMENT effectiveness , *BLIND experiment , *DIAGNOSIS ,TYPHOID fever diagnosis - Abstract
Background: Undifferentiated febrile illness (UFI) includes typhoid and typhus fevers and generally designates fever without any localizing signs. UFI is a great therapeutic challenge in countries like Nepal because of the lack of available point-of-care, rapid diagnostic tests. Often patients are empirically treated as presumed enteric fever. Due to the development of high-level resistance to traditionally used fluoroquinolones against enteric fever, azithromycin is now commonly used to treat enteric fever/UFI. The re-emergence of susceptibility of Salmonella typhi to co-trimoxazole makes it a promising oral treatment for UFIs in general. We present a protocol of a randomized controlled trial of azithromycin versus co-trimoxazole for the treatment of UFI.Methods/design: This is a parallel-group, double-blind, 1:1, randomized controlled trial of co-trimoxazole versus azithromycin for the treatment of UFI in Nepal. Participants will be patients aged 2 to 65 years, presenting with fever without clear focus for at least 4 days, complying with other study criteria and willing to provide written informed consent. Patients will be randomized either to azithromycin 20 mg/kg/day (maximum 1000 mg/day) in a single daily dose and an identical placebo or co-trimoxazole 60 mg/kg/day (maximum 3000 mg/day) in two divided doses for 7 days. Patients will be followed up with twice-daily telephone calls for 7 days or for at least 48 h after they become afebrile, whichever is later; by home visits on days 2 and 4 of treatment; and by hospital visits on days 7, 14, 28 and 63. The endpoints will be fever clearance time, treatment failure, time to treatment failure, and adverse events. The estimated sample size is 330. The primary analysis population will be all the randomized population and subanalysis will be repeated on patients with blood culture-confirmed enteric fever and culture-negative patients.Discussion: Both azithromycin and co-trimoxazole are available in Nepal and are extensively used in the treatment of UFI. Therefore, it is important to know the better orally administered antimicrobial to treat enteric fever and other UFIs especially against the background of fluoroquinolone-resistant enteric fever.Trial Registration: ClinicalTrials.gov, ID: NCT02773407 . Registered on 5 May 2016. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
7. Findings of Cognitive Impairment at High Altitude: Relationships to Acetazolamide Use and Acute Mountain Sickness.
- Author
-
Phillips, Lara, Basnyat, Buddha, Chang, Yuchiao, Swenson, Erik R., and Harris, N. Stuart
- Subjects
- *
MILD cognitive impairment , *MOUNTAIN sickness , *ACETAZOLAMIDE , *CENTRAL nervous system , *DRUG utilization - Abstract
Phillips, Lara, Buddha Basnyat, Yuchiao Chang, Erik R. Swenson, and N. Stuart Harris. Findings of cognitive impairment at high altitude: relationships to acetazolamide use and acute mountain sickness. High Alt Med Biol. 18:121-127, 2017. Objective: Acute mountain sickness (AMS) is defined by patient-reported symptoms using the Lake Louise Score (LLS), which provides limited insight into any possible underlying central nervous system (CNS) dysfunction. Some evidence suggests AMS might coexist with altered neural functioning. Cognitive impairment (CI) may go undetected unless a sensitive test is applied. Our hypothesis was that a standardized test for mild CI would provide an objective measure of CNS dysfunction, which may correlate with the symptoms of AMS and so provide a potential new tool to better characterize altitude-related CNS dysfunction. We compared a cognitive screening tool with the LLS to see if it correlated with CNS dysfunction. Methods: Adult native English-speaking subjects visiting Himalayan Rescue Association aid stations in Nepal at 3520 m (11,548 ft) and 4550 m (14,927 ft) were recruited. Subjects were administered the LLS and a slightly modified version of the environmental Quick mild cognitive impairment screen (eQmci). Medication use for altitude illness was recorded. Scores were compared using the Spearman's correlation coefficient. Data also included medication use. Results: Seventy-nine subjects were enrolled. A cut-off of three or greater was used for the LLS to diagnose AMS and 67 or less for the eQmci to diagnose CI. There were 22 (28%) subjects who met criteria for AMS and 17 (22%) subjects who met criteria for CI. There was a weak correlation ( r2 = 0.06, p = 0.04) between eQmci score and LLS. In matched subjects with identical LLS, recent acetazolamide use was associated with significantly more CI. Conclusion: Field assessment of CI using a rapid standardized tool demonstrated that a substantial number of subjects were found to have mild CI following rapid ascent to 3520-4550 m (11,548-14,927 ft). The weak correlation between the LLS and eQmci suggests that AMS does not result in CI. Use of acetazolamide appears to be associated with CI at all levels of AMS severity. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
8. Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomised controlled trial.
- Author
-
Arjyal, Amit, Basnyat, Buddha, Nhan, Ho Thi, Koirala, Samir, Giri, Abhishek, Joshi, Niva, Shakya, Mila, Pathak, Kamal Raj, Mahat, Saruna Pathak, Prajapati, Shanti Pradhan, Adhikari, Nabin, Thapa, Rajkumar, Merson, Laura, Gajurel, Damodar, Lamsal, Kamal, Lamsal, Dinesh, Yadav, Bharat Kumar, Shah, Ganesh, Shrestha, Poojan, and Dongol, Sabina
- Subjects
- *
TYPHOID fever , *CEFTRIAXONE , *CEPHALOSPORINS , *FLUOROQUINOLONES , *PATIENTS , *THERAPEUTICS , *ANTIBIOTICS , *QUINOLONE antibacterial agents , *COMPARATIVE studies , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *SALMONELLA , *EVALUATION research , *RANDOMIZED controlled trials , *TREATMENT effectiveness - Abstract
Background: Because treatment with third-generation cephalosporins is associated with slow clinical improvement and high relapse burden for enteric fever, whereas the fluoroquinolone gatifloxacin is associated with rapid fever clearance and low relapse burden, we postulated that gatifloxacin would be superior to the cephalosporin ceftriaxone in treating enteric fever.Methods: We did an open-label, randomised, controlled, superiority trial at two hospitals in the Kathmandu valley, Nepal. Eligible participants were children (aged 2-13 years) and adult (aged 14-45 years) with criteria for suspected enteric fever (body temperature ≥38·0°C for ≥4 days without a focus of infection). We randomly assigned eligible patients (1:1) without stratification to 7 days of either oral gatifloxacin (10 mg/kg per day) or intravenous ceftriaxone (60 mg/kg up to 2 g per day for patients aged 2-13 years, or 2 g per day for patients aged ≥14 years). The randomisation list was computer-generated using blocks of four and six. The primary outcome was a composite of treatment failure, defined as the occurrence of at least one of the following: fever clearance time of more than 7 days after treatment initiation; the need for rescue treatment on day 8; microbiological failure (ie, blood cultures positive for Salmonella enterica serotype Typhi, or Paratyphi A, B, or C) on day 8; or relapse or disease-related complications within 28 days of treatment initiation. We did the analyses in the modified intention-to-treat population, and subpopulations with either confirmed blood-culture positivity, or blood-culture negativity. The trial was powered to detect an increase of 20% in the risk of failure. This trial was registered at ClinicalTrials.gov, number NCT01421693, and is now closed.Findings: Between Sept 18, 2011, and July 14, 2014, we screened 725 patients for eligibility. On July 14, 2014, the trial was stopped early by the data safety and monitoring board because S Typhi strains with high-level resistance to ciprofloxacin and gatifloxacin had emerged. At this point, 239 were in the modified intention-to-treat population (120 assigned to gatifloxacin, 119 to ceftriaxone). 18 (15%) patients who received gatifloxacin had treatment failure, compared with 19 (16%) who received ceftriaxone (hazard ratio [HR] 1·04 [95% CI 0·55-1·98]; p=0·91). In the culture-confirmed population, 16 (26%) of 62 patients who received gatifloxacin failed treatment, compared with four (7%) of 54 who received ceftriaxone (HR 0·24 [95% CI 0·08-0·73]; p=0·01). Treatment failure was associated with the emergence of S Typhi exhibiting resistance against fluoroquinolones, requiring the trial to be stopped. By contrast, in patients with a negative blood culture, only two (3%) of 58 who received gatifloxacin failed treatment versus 15 (23%) of 65 who received ceftriaxone (HR 7·50 [95% CI 1·71-32·80]; p=0·01). A similar number of non-serious adverse events occurred in each treatment group, and no serious events were reported.Interpretation: Our results suggest that fluoroquinolones should no longer be used for treatment of enteric fever in Nepal. Additionally, under our study conditions, ceftriaxone was suboptimum in a high proportion of patients with culture-negative enteric fever. Since antimicrobials, specifically fluoroquinolones, are one of the only routinely used control measures for enteric fever, the assessment of novel diagnostics, new treatment options, and use of existing vaccines and development of next-generation vaccines are now a high priority.Funding: Wellcome Trust and Li Ka Shing Foundation. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
9. Diagnostics for Typhoid Fever: Current Perspectives and Future Outlooks for Product Development and Access.
- Author
-
Sapkota, Jyotshna, Roberts, Tamalee, Basnyat, Buddha, Baker, Stephen, Hampton, Lee M, and Dittrich, Sabine
- Subjects
- *
TYPHOID fever , *SALMONELLA diseases , *NEW product development , *SALMONELLA typhi , *RAPID diagnostic tests , *MIDDLE-income countries - Abstract
Typhoid is an enteric disease caused by Salmonella Typhi. Like many febrile illnesses, typhoid presents with nonspecific symptoms. In routine healthcare settings in low- and middle-income countries, typhoid fever is suspected and treated empirically. Though many diagnostic tests are available for typhoid diagnosis, there are currently no diagnostic tests that meet ideal requirements for sensitivity, specificity, speed, and cost-effectiveness. With introduction of typhoid conjugate vaccine, it is essential to explore the current and future typhoid approach in the context of use case and access to ensure their utilization for disease control. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Sustained use of biogas fuel and blood pressure among women in rural Nepal.
- Author
-
Neupane, Maniraj, Basnyat, Buddha, Fischer, Rainald, Froeschl, Guenter, Wolbers, Marcel, and Rehfuess, Eva A
- Subjects
- *
BIOGAS , *BLOOD pressure , *WOMEN , *AIR pollution , *CARDIOVASCULAR diseases risk factors , *POSTMENOPAUSE , *SYSTOLIC blood pressure , *SOLID fuel reactors - Abstract
Background More than two fifths of the world's population cook with solid fuels and are exposed to household air pollution (HAP). As of now, no studies have assessed whether switching to alternative fuels like biogas could impact cardiovascular health among cooks previously exposed to solid fuel use. Methods We conducted a propensity score matched cross-sectional study to explore if the sustained use of biogas fuel for at least ten years impacts blood pressure among adult female cooks of rural Nepal. We recruited one primary cook ≥30 years of age from each biogas (219 cooks) and firewood (300 cooks) using household and measured their systolic (SBP) and diastolic blood pressure (DBP). Household characteristics, kitchen ventilation and 24-h kitchen carbon monoxide were assessed. We matched cooks by age, body mass index and socio-economic status score using propensity scores and investigated the effect of biogas use through multivariate regression models in two age groups, 30–50 years and >50 years to account for any post-menopausal changes. Results We found substantially reduced 24-h kitchen carbon monoxide levels among biogas-using households. After matching and adjustment for smoking, kitchen characteristics, ventilation status and additional fuel use, the use of biogas was associated with 9.8 mmHg lower SBP [95% confidence interval (CI), −20.4 to 0.8] and 6.5 mmHg lower DBP (95% CI, −12.2 to −0.8) compared to firewood users among women >50 years of age. In this age group, biogas use was also associated with 68% reduced odds [Odds ratio 0.32 (95% CI, 0.14 to 0.71)] of developing hypertension. These effects, however, were not identified in younger women aged 30–50 years. Conclusions Sustained use of biogas for cooking may protect against cardiovascular disease by lowering the risk of high blood pressure, especially DBP, among older female cooks. These findings need to be confirmed in longitudinal or experimental studies. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
11. High Altitude Pilgrimage Medicine.
- Author
-
Basnyat, Buddha
- Subjects
- *
MOUNTAIN sickness , *PILGRIMS & pilgrimages , *INFLUENCE of altitude , *HIKERS , *EPIDEMIOLOGY , *CORONARY disease , *DIABETES complications , *PEPTIC ulcer - Abstract
Religious pilgrims have been going to high altitude pilgrimages long before trekkers and climbers sojourned in high altitude regions, but the medical literature about high altitude pilgrimage is sparse. Gosainkunda Lake (4300 m) near Kathmandu, Nepal, and Shri Amarnath Yatra (3800 m) in Sri Nagar, Kashmir, India, are the two sites in the Himalayas from where the majority of published reports of high altitude pilgrimage have originated. Almost all travels to high altitude pilgrimages are characterized by very rapid ascents by large congregations, leading to high rates of acute mountain sickness (AMS). In addition, epidemiological studies of pilgrims from Gosainkunda Lake show that some of the important risk factors for AMS in pilgrims are female sex and older age group. Studies based on the Shri Amarnath Yatra pilgrims show that coronary artery disease, complications of diabetes, and peptic ulcer disease are some of the common, important reasons for admission to hospital during the trip. In this review, the studies that have reported these and other relevant findings will be discussed and appropriate suggestions made to improve pilgrims' safety at high altitude. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
12. The Light Is Gone: Tribute to Prakash Adhikari, Executive Director of the Himalayan Rescue Association.
- Author
-
Basnyat, Buddha, Freer, Luanne, and Zafren, Ken
- Subjects
- *
EXECUTIVES , *CIVILIAN evacuation , *VOLUNTEER service , *HIKERS , *MEDICAL personnel , *MOUNTAINEERING - Abstract
Prakash first collected all the certificates from the volunteer doctors, had these vetted by the health professionals at the HRA, and then started his rounds of the ministries and approval boards, with the generous and necessary help of other HRA officials. Graph: ham.2020.0213 figure1.jpg Prakash Adhikari, Executive Director of the Himalayan Rescue Association (HRA), died at the age of 54 years in Kathmandu, Nepal, on October 23, 2020, from COVID-19 pneumonia. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
13. Gatifloxacin Versus Ofloxacin for the Treatment of Uncomplicated Enteric Fever in Nepal: An Open-Label, Randomized, Controlled Trial.
- Author
-
Koirala, Samir, Basnyat, Buddha, Arjyal, Amit, Shilpakar, Olita, Shrestha, Kabina, Shrestha, Rishav, Shrestha, Upendra Man, Agrawal, Krishna, Koirala, Kanika Deshpande, Thapa, Sudeep Dhoj, Karkey, Abhilasha, Dongol, Sabina, Giri, Abhishek, Shakya, Mila, Pathak, Kamal Raj, Campbell, James, Baker, Stephen, Farrar, Jeremy, Wolbers, Marcel, and Dolecek, Christiane
- Subjects
- *
TYPHOID fever , *SALMONELLA enterica serovar Typhi , *BACTERIOPHAGE typing , *YOUNG adults , *DRUG efficacy , *TREATMENT failure ,WESTERN countries - Abstract
Background: Fluoroquinolones are the most commonly used group of antimicrobials for the treatment of enteric fever, but no direct comparison between two fluoroquinolones has been performed in a large randomised trial. An open-label randomized trial was conducted to investigate whether gatifloxacin is more effective than ofloxacin in the treatment of uncomplicated enteric fever caused by nalidixic acid-resistant Salmonella enterica serovars Typhi and Paratyphi A. Methodology and Principal Findings: Adults and children clinically diagnosed with uncomplicated enteric fever were enrolled in the study to receive gatifloxacin (10 mg/kg/day) in a single dose or ofloxacin (20 mg/kg/day) in two divided doses for 7 days. Patients were followed for six months. The primary outcome was treatment failure in patients infected with nalidixic acid resistant isolates. 627 patients with a median age of 17 (IQR 9–23) years were randomised. Of the 218 patients with culture confirmed enteric fever, 170 patients were infected with nalidixic acid-resistant isolates. In the ofloxacin group, 6 out of 83 patients had treatment failure compared to 5 out of 87 in the gatifloxacin group (hazard ratio [HR] of time to failure 0.81, 95% CI 0.25 to 2.65, p = 0.73). The median time to fever clearance was 4.70 days (IQR 2.98–5.90) in the ofloxacin group versus 3.31 days (IQR 2.29–4.75) in the gatifloxacin group (HR = 1.59, 95% CI 1.16 to 2.18, p = 0.004). The results in all blood culture-confirmed patients and all randomized patients were comparable. Conclusion: Gatifloxacin was not superior to ofloxacin in preventing failure, but use of gatifloxacin did result in more prompt fever clearance time compared to ofloxacin. Trial registration: ISRCTN 63006567 (www.controlled-trials.com). Author Summary: Enteric fever, which comprises of typhoid and paratyphoid fevers, is common in many developing countries. It is also sometimes seen in the Western world in returning travellers. This present study of uncomplicated enteric fever in an outpatient setting in a hospital in Kathmandu, Nepal compared the newer gatifloxacin with the widely-used ofloxacin (two drugs of the fluroquinolone class) in the treatment of this illness. Although fluroquinolones are commonly considered the main group of drugs in the treatment of enteric fever, there have not been comparisons of efficacy between two drugs in this same class in the treatment of enteric fever. Furthermore, certain strains of enteric fever organism called nalidixic-acid resistant strains are proving very difficult to treat in both the local population and the Western travellers. The study focused primarily on the efficacy of the 2 drugs against these particular strains. The results revealed that both drugs were effective but gatifloxacin decreased the patient's fever more rapidly than ofloxacin. Dysglycemia was noted in a 35-year-old woman taking gatifloxacin who did not disclose a pre-existing diagnosis of diabetes at time of enrollment, but not in any other healthy child or young adult. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
14. Gatifloxacin Versus Ofloxacin for the Treatment of Uncomplicated Enteric Fever in Nepal: An Open-Label, Randomized, Controlled Trial.
- Author
-
Koirala, Samir, Basnyat, Buddha, Arjyal, Amit, Shilpakar, Olita, Shrestha, Kabina, Shrestha, Rishav, Shrestha, Upendra Man, Agrawal, Krishna, Koirala, Kanika Deshpande, Thapa, Sudeep Dhoj, Karkey, Abhilasha, Dongol, Sabina, Giri, Abhishek, Shakya, Mila, Pathak, Kamal Raj, Campbell, James, Baker, Stephen, Farrar, Jeremy, Wolbers, Marcel, and Dolecek, Christiane
- Subjects
- *
FLUOROQUINOLONES , *TYPHOID fever treatment , *RANDOMIZED controlled trials , *DRUG resistance in bacteria , *HEALTH outcome assessment , *THERAPEUTICS - Abstract
Background: Fluoroquinolones are the most commonly used group of antimicrobials for the treatment of enteric fever, but no direct comparison between two fluoroquinolones has been performed in a large randomised trial. An open-label randomized trial was conducted to investigate whether gatifloxacin is more effective than ofloxacin in the treatment of uncomplicated enteric fever caused by nalidixic acid-resistant Salmonella enterica serovars Typhi and Paratyphi A. Methodology and Principal Findings: Adults and children clinically diagnosed with uncomplicated enteric fever were enrolled in the study to receive gatifloxacin (10 mg/kg/day) in a single dose or ofloxacin (20 mg/kg/day) in two divided doses for 7 days. Patients were followed for six months. The primary outcome was treatment failure in patients infected with nalidixic acid resistant isolates. 627 patients with a median age of 17 (IQR 9–23) years were randomised. Of the 218 patients with culture confirmed enteric fever, 170 patients were infected with nalidixic acid-resistant isolates. In the ofloxacin group, 6 out of 83 patients had treatment failure compared to 5 out of 87 in the gatifloxacin group (hazard ratio [HR] of time to failure 0.81, 95% CI 0.25 to 2.65, p = 0.73). The median time to fever clearance was 4.70 days (IQR 2.98–5.90) in the ofloxacin group versus 3.31 days (IQR 2.29–4.75) in the gatifloxacin group (HR = 1.59, 95% CI 1.16 to 2.18, p = 0.004). The results in all blood culture-confirmed patients and all randomized patients were comparable. Conclusion: Gatifloxacin was not superior to ofloxacin in preventing failure, but use of gatifloxacin did result in more prompt fever clearance time compared to ofloxacin. Trial registration: ISRCTN 63006567 (www.controlled-trials.com). [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
15. Strengthening Altitude Knowledge: A Delphi Study to Define Minimum Knowledge of Altitude Illness for Laypersons Traveling to High Altitude.
- Author
-
Berendsen, Remco R., Bärtsch, Peter, Basnyat, Buddha, Berger, Marc Moritz, Hackett, Peter, Luks, Andrew M., Richalet, Jean-Paul, Zafren, Ken, Kayser, Bengt, Anholm, J, Auerbach, P.S, Beidleman, B.A, Bloch, K.E, Brodmann, M, Brugger, H, Burtscher, M, Dehnert, C, Dumont, L, Faulhaber, M, and Fischer, R
- Subjects
- *
DELPHI method , *ALTITUDES , *MOUNTAIN sickness , *LAYPERSONS , *CEREBRAL edema , *PULMONARY edema - Abstract
Berendsen, Remco R., Peter Bärtsch, Buddha Basnyat, Marc Moritz Berger, Peter Hackett, Andrew M. Luks, Jean-Paul Richalet, Ken Zafren, Bengt Kayser, and the STAK Plenary Group. Strengthening altitude knowledge: a Delphi study to define minimum knowledge of altitude illness for laypersons traveling to high altitude. High Alt Med Biol. 23:330–337, 2022. Introduction: A lack of knowledge among laypersons about the hazards of high-altitude exposure contributes to morbidity and mortality from acute mountain sickness (AMS), high-altitude cerebral edema (HACE), and high-altitude pulmonary edema (HAPE) among high-altitude travelers. There are guidelines regarding the recognition, prevention, and treatment of acute-altitude illness for experts, but essential knowledge for laypersons traveling to high altitudes has not been defined. We sought expert consensus on the essential knowledge required for people planning to travel to high altitudes. Methods: The Delphi method was used. The panel consisted of two moderators, a core expert group and a plenary expert group. The moderators made a preliminary list of statements defining the desired minimum knowledge for laypersons traveling to high altitudes, based on the relevant literature. These preliminary statements were then reviewed, supplemented, and modified by a core expert group. A list of 33 statements was then presented to a plenary group of experts in successive rounds. Results: It took three rounds to reach a consensus. Of the 10 core experts invited, 7 completed all the rounds. Of the 76 plenary experts, 41 (54%) participated in Round 1, and of these 41 a total of 32 (78%) experts completed all three rounds. The final list contained 28 statements in 5 categories (altitude physiology, sleeping at altitude, AMS, HACE, and HAPE). This list represents an expert consensus on the desired minimum knowledge for laypersons planning high-altitude travel. Conclusion: Using the Delphi method, the STrengthening Altitude Knowledge initiative yielded a set of 28 statements representing essential learning objectives for laypersons who plan to travel to high altitudes. This list could be used to develop educational interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Drug-resistant bacterial infections: We need urgent action and investment that focus on the weakest link.
- Author
-
Dolecek, Christiane, Shakoor, Sadia, Basnyat, Buddha, Okwor, Tochi, and Sartorius, Benn
- Subjects
- *
BACTERIAL diseases , *INFECTION prevention , *INFECTION control , *MIDDLE-income countries , *MEDICAL care - Abstract
Despite high mortality and morbidity, drug-resistant bacterial infections remain the forgotten pandemic. We argue for strengthening of diagnostics, WASH (water, sanitation, and hygiene) and infection prevention and control to reduce drug-resistant infections, as an integral part of sustainable high-quality health services, particularly in low- and middle-income countries. In a world of multiple crises, the momentum to tackle drug-resistant bacterial infections must not fall further behind. A renewed focus is needed on global infection prevention and control strategies, which are lagging behind in many countries, diagnosis and good antimicrobial stewardship. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial
- Author
-
Arjyal, Amit, Basnyat, Buddha, Koirala, Samir, Karkey, Abhilasha, Dongol, Sabina, Agrawaal, Krishna Kumar, Shakya, Nikki, Shrestha, Kabina, Sharma, Manish, Lama, Sanju, Shrestha, Kasturi, Khatri, Nely Shrestha, Shrestha, Umesh, Campbell, James I, Baker, Stephen, Farrar, Jeremy, Wolbers, Marcel, and Dolecek, Christiane
- Subjects
- *
FLUOROQUINOLONES , *CHLORAMPHENICOL , *TYPHOID fever treatment , *MICROBIOLOGY , *RANDOMIZED controlled trials , *HEALTH outcome assessment - Abstract
Summary: Background: We aimed to investigate whether gatifloxacin, a new generation and affordable fluoroquinolone, is better than chloramphenicol for the treatment of uncomplicated enteric fever in children and adults. Methods: We did an open-label randomised superiority trial at Patan Hospital, Kathmandu, Nepal, to investigate whether gatifloxacin is more effective than chloramphenicol for treating uncomplicated enteric fever. Children and adults clinically diagnosed with enteric fever received either gatifloxacin (10 mg/kg) once a day for 7 days, or chloramphenicol (75 mg/kg per day) in four divided doses for 14 days. Patients were randomly allocated treatment (1:1) in blocks of 50, without stratification. Allocations were placed in sealed envelopes opened by the study physician once a patient was enrolled into the trial. Masking was not possible because of the different formulations and ways of giving the two drugs. The primary outcome measure was treatment failure, which consisted of at least one of the following: persistent fever at day 10, need for rescue treatment, microbiological failure, relapse until day 31, and enteric-fever-related complications. The primary outcome was assessed in all patients randomly allocated treatment and reported separately for culture-positive patients and for all patients. Secondary outcome measures were fever clearance time, late relapse, and faecal carriage. The trial is registered on controlled-trials.com, number ISRCTN 53258327. Findings: 844 patients with a median age of 16 (IQR 9–22) years were enrolled in the trial and randomly allocated a treatment. 352 patients had blood-culture-confirmed enteric fever: 175 were treated with chloramphenicol and 177 with gatifloxacin. 14 patients had treatment failure in the chloramphenicol group, compared with 12 in the gatifloxacin group (hazard ratio [HR] of time to failure 0·86, 95% CI 0·40–1·86, p=0·70). The median time to fever clearance was 3·95 days (95% CI 3·68–4·68) in the chloramphenicol group and 3·90 days (3·58–4·27) in the gatifloxacin group (HR 1·06, 0·86–1·32, p=0·59). At 1 month only, three of 148 patients were stool-culture positive in the chloramphenicol group and none in the gatifloxacin group. At the end of 3 months only one person had a positive stool culture in the chloramphenicol group. There were no other positive stool cultures even at the end of 6 months. Late relapses were noted in three of 175 patients in the culture-confirmed chloramphenicol group and two of 177 in the gatifloxacin group. There were no culture-positive relapses after day 62. 99 patients (24%) experienced 168 adverse events in the chloramphenicol group and 59 (14%) experienced 73 events in the gatifloxacin group. Interpretation: Although no more efficacious than chloramphenicol, gatifloxacin should be the preferred treatment for enteric fever in developing countries because of its shorter treatment duration and fewer adverse events. Funding: Wellcome Trust. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
18. Brain blood flow in Andean and Himalayan high-altitude populations: evidence of different traits for the same environmental constraint.
- Author
-
Jansen, Gerard FA and Basnyat, Buddha
- Subjects
- *
CEREBRAL circulation , *POPULATION , *CEREBRAL anoxia , *OXYGEN in the body , *HEMATOCRIT , *NITRIC oxide - Abstract
Humans have populated the Tibetan plateau much longer than the Andean Altiplano. It is thought that the difference in length of occupation of these altitudes has led to different responses to the stress of hypoxia. As such, Andean populations have higher hematocrit levels than Himalayans. In contrast, Himalayans have increased circulation to certain organ systems to meet tissue oxygen demand. In this study, we hypothesize that cerebral blood flow (CBF) is higher in Himalayans than in Andeans. Using a MEDLINE and EMBASE search, we included 10 studies that investigated CBF in Andeans and Himalayans between 3,658 and 4,330 m altitude. The CBF values were corrected for differences in hematocrit and arterial oxygen saturation. The data of these studies show a mean hematocrit of 50% in Himalayans and 54.1% in Andeans. Arterial oxygen saturation was 86.9% in Andeans and 88.4% in Himalayans. The CBF in Himalayans was slightly elevated compared with sea-level subjects, and was 24% higher compared with Andeans. After correction for hematorit and arterial oxygen saturation, CBF was ∼20% higher in Himalayans compared with Andeans. Altered brain metabolism in Andeans, and/or increased nitric oxide availability in Himalayans may have a role to explain this difference in brain blood flow. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
19. Letter to the Editor: COVID-19 Lung Injury Is Different From High Altitude Pulmonary Edema.
- Author
-
Brugger, Hermann, Basnyat, Buddha, Ellerton, John, Hefti, Urs, Strapazzon, Giacomo, and Zafren, Ken
- Subjects
- *
COVID-19 , *PULMONARY edema , *LUNG injuries , *RESPIRATORY infections , *ORGANS (Anatomy) , *ALTITUDES - Abstract
Patients with COVID-19 lung injury typically present with a benign upper respiratory infection that progresses to severe acute respiratory distress syndrome (ARDS; Gattinoni et al., 2020). COVID-19 lung injury and HAPE are fundamentally different in pathogenesis, pathophysiology, prognosis, and treatment. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
20. High-altitude illness.
- Author
-
Basnyat, Buddha and Murdoch, David R
- Subjects
- *
MOUNTAIN sickness , *PULMONARY edema , *INFLUENCE of altitude , *EDEMA , *LUNG diseases , *BRAIN diseases , *PREVENTIVE medicine - Abstract
High-altitude illness is the collective term for acute mountain sickness (AMS), high-altitude cerebral oedema (HACE), and high-altitude pulmonary oedema (HAPE). The pathophysiology of these syndromes is not completely understood, although studies have substantially contributed to the current understanding of several areas. These areas include the role and potential mechanisms of brain swelling in AMS and HACE, mechanisms accounting for exaggerated pulmonary hypertension in HAPE, and the role of inflammation and alveolar-fluid clearance in HAPE. Only limited information is available about the genetic basis of high-altitude illness, and no clear associations between gene polymorphisms and susceptibility have been discovered. Gradual ascent will always be the best strategy for preventing high-altitude illness, although chemoprophylaxis may be useful in some situations. Despite investigation of other agents, acetazolamide remains the preferred drug for preventing AMS. The next few years are likely to see many advances in the understanding of the causes and management of high-altitude illness. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
21. Infections at High Altitude.
- Author
-
Basnyat, Buddha, Cumbo, Thomas A., and Edelman, Robert
- Subjects
- *
PATHOGENIC microorganisms , *GASTROINTESTINAL diseases ,INFECTION treatment - Abstract
Every year, thousands of outdoor trekkers worldwide visit high-altitude (2500 m) destinations. Although high-altitude areas per se do not harbor any specific agents, it is important to know the pathogens encountered in the mountains to be better able to help the ill sojourner at high altitude. These are the same pathogens prevalent in the surrounding lowlands, but various factors such as immunomodulation, hypoxia, physiological adaptation, and harsh environmental stressors at high altitude may enhance susceptibility to these pathogens. Against this background, various gastrointestinal, respiratory, der-matological, neurological, and other infections encountered at high altitude are discussed. Because there are few published data on infections at high altitude, this review is largely anecdotal and based on personal experience. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
22. A retrospective investigation of the population structure and geospatial distribution of Salmonella Paratyphi A in Kathmandu, Nepal.
- Author
-
Mylona, Elli, Pham Thanh, Duy, Keane, Jacqueline A., Dongol, Sabina, Basnyat, Buddha, Dolecek, Christiane, Voong Vinh, Phat, Tran Vu Thieu, Nga, Nguyen Thi Nguyen, To, Karkey, Abhilasha, and Baker, Stephen
- Subjects
- *
SALMONELLA enterica serovar Typhi , *TYPHOID fever , *LOCATION data , *SALMONELLA typhi , *WHOLE genome sequencing , *SALMONELLA - Abstract
Salmonella Paratyphi A, one of the major etiologic agents of enteric fever, has increased in prevalence in recent decades in certain endemic regions in comparison to S. Typhi, the most prevalent cause of enteric fever. Despite this increase, data on the prevalence and molecular epidemiology of S. Paratyphi A remain generally scarce. Here, we analysed the whole genome sequences of 216 S. Paratyphi A isolates originating from Kathmandu, Nepal between 2005 and 2014, of which 200 were from patients with acute enteric fever and 16 from the gallbladder of people with suspected chronic carriage. By exploiting the recently developed genotyping framework for S. Paratyphi A (Paratype), we identified several genotypes circulating in Kathmandu. Notably, we observed an unusual clonal expansion of genotype 2.4.3 over a four-year period that spread geographically and systematically replaced other genotypes. This rapid genotype replacement is hypothesised to have been driven by both reduced susceptibility to fluoroquinolones and genetic changes to virulence factors, such as functional and structural genes encoding the type 3 secretion systems. Finally, we show that person-to-person is likely the most common mode of transmission and chronic carriers seem to play a limited role in maintaining disease circulation. Author summary: Enteric (typhoid) fever is caused by bacteria of Salmonella enterica species, specifically Salmonella Typhi and Salmonella Paratyphi A. While the former is most commonly identified as the causative agent of enteric fever, S. Paratyphi A is increasing in prevalence in many endemic areas like Nepal. However, the understanding of the phylogenetic structure and population dynamics of this organism, as well as transmission patterns, remains incomplete. Here, we provide a detailed phylogenetic analysis of S. Paratyphi A isolated from enteric fever patients in Nepal through whole genome sequence analysis, combined with epidemiological observations, such as water source use, and chronological and location data. We observed an unusual expansion of a genotype (genetic ID) that replaced other genotypes in the area, indicative of changes in circulating population composition. This expansion is hypothesised to have been driven by reduction in antibiotic susceptibility and changes on bacterial structures that are important for pathogenicity. Our data also suggest person-to-person as the most likely mode of transmission for this pathogen. Understanding of S. Paratyphi A population structure, sources of infection, and transmission will help develop policies for enteric fever management, particularly prior to vaccine introduction, as changes in population composition may affect vaccine efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Acclimatizing with Acetazolamide.
- Author
-
Basnyat, Buddha
- Subjects
- *
ACETAZOLAMIDE , *MOUNTAIN sickness , *PREVENTION - Abstract
An introduction is presented in which the editor discusses the use of acetazolamide for preventing acute mountain sickness (AMS).
- Published
- 2012
- Full Text
- View/download PDF
24. Randomised,controlled trial of ginkgo biloba and acetazolamide for prevention of acute mountain sickness: the prevention of high altitude illness trial (PHAIT).
- Author
-
Gertsch, Jeffrey H., Basnyat, Buddha, Johnson, E. WIlliam, Onopa, Janet, and Holck, Peter S.
- Subjects
- *
MOUNTAIN sickness , *GINKGO , *DIURETICS , *PLACEBOS , *HEADACHE - Abstract
Objective: To evaluate the efficacy of ginkgo biloba, acetazolamide, and their combination as prophylaxis against acute mountain sickness. Design: Prospective, double blind, randomised, placebo controlled trial. Setting: Approach to Mount Everest base camp in the Nepal Himalayas at 4280 m or 4358 m and study end point at 4928 m during October and November 2002. Participants 614 healthy western trekkers (487 completed the trial) assigned to receive ginkgo, acetazolamide, combined acetazolamide and ginkgo, or placebo, initially taking at least three or four doses before continued ascent. Main outcome measures: Incidence measured by Lake Louise acute mountain sickness score ≥3 with headache and one other symptom. Secondary outcome measures included blood oxygen content, severity of syndrome (Lake Louise scores ≥5), incidence of headache, and severity of headache. Results: Ginkgo was not significantly different from placebo for any outcome; however participants in the acetazolamide group showed significant levels of protection. The incidence of acute mountain sickness was 34%for placebo, 12%for acetazolamide (odds ratio 3.76,95%confidence interval 1.91 to 7.39, number needed to treat 4), 35% for ginkgo (0.95,0.56 to 1.62), and 14%for combined ginkgo and acetazolamide (3.04,1.62 to 5.69). The proportion of patients with increased severity of acute mountain sickness was 18%for placebo, 3%for acetazolamide (6.46,2.15 to 19.40, number needed to treat 7), 18% for ginkgo (1,0.52 to 1.90), and 7%for combined ginkgo and acetazolamide (2.95,1.30 to 6.70). Conclusions: When compared with placebo, ginkgo is not effective at preventing acute mountain sickness. Acetazolamide 250 mg twice daily afforded robust protection against symptoms of acute mountain sickness. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
25. The Identification of Enteric Fever-Specific Antigens for Population-Based Serosurveillance.
- Author
-
Mylona, Elli, Hefele, Lisa, Thieu, Nga Tran Vu, Van, Tan Trinh, Minh, Chau Nguyen Ngoc, Tuan, Anh Tran, Karkey, Abhilasha, Dongol, Sabina, Basnyat, Buddha, Vinh, Phat Voong, Dan, Thanh Ho Ngoc, Russell, Paula, Charles, Richelle C, Parry, Christopher M, and Baker, Stephen
- Abstract
Background Enteric fever, caused by Salmonella enterica serovars Typhi and Paratyphi A, is a major public health problem in low- and middle-income countries. Moderate sensitivity and scalability of current methods likely underestimate enteric fever burden. Determining the serological responses to organism-specific antigens may improve incidence measures. Methods Plasma samples were collected from blood culture-confirmed enteric fever patients, blood culture-negative febrile patients over the course of 3 months, and afebrile community controls. A panel of 17 Salmonella Typhi and Paratyphi A antigens was purified and used to determine antigen-specific antibody responses by indirect ELISAs. Results The antigen-specific longitudinal antibody responses were comparable between enteric fever patients, patients with blood culture-negative febrile controls, and afebrile community controls for most antigens. However, we found that IgG responses against STY1479 (YncE), STY1886 (CdtB), STY1498 (HlyE), and the serovar-specific O2 and O9 antigens were greatly elevated over a 3-month follow up period in S. Typhi/ S. Paratyphi A patients compared to controls, suggesting seroconversion. Conclusions We identified a set of antigens as good candidates to demonstrate enteric fever exposure. These targets can be used in combination to develop more sensitive and scalable approaches to enteric fever surveillance and generate invaluable epidemiological data for informing vaccine policies. Clinical Trial Registration ISRCTN63006567. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Higher ascent, trouble breathing: High altitude pulmonary edema (HAPE).
- Author
-
Thapa, Simant Singh and Basnyat, Buddha
- Subjects
- *
PULMONARY edema , *DISEASES in men , *HIKING - Published
- 2018
- Full Text
- View/download PDF
27. Chronic Diarrhea in a Traveler: Cyclosporiasis.
- Author
-
Thapa, Simant Singh and Basnyat, Buddha
- Subjects
- *
DIARRHEA , *TRAVEL hygiene , *CHRONIC diseases - Published
- 2017
- Full Text
- View/download PDF
28. Does age have an impact on acute mountain sickness? A systematic review.
- Author
-
Gianfredi, Vincenza, Albano, Luciana, Basnyat, Buddha, and Ferrara, Pietro
- Abstract
Acute mountain sickness (AMS) is the most common form of illness at high altitude; however, it is still unclear whether age is a protective factor or a risk factor for the development of AMS in travellers. In recent decades, the number of travellers aged 60 years or older is increasing. Thus, the care of older travellers is a long-standing issue in travel medicine. This study aims to systematically review the current state of knowledge related to the effect of old age on the risk of AMS. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used, and the following databases were consulted: PubMed/Medline, Embase, Europe PubMed Central (EuropePMC), World Health Organization Library Database (WHOLIS) and Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS). The search yielded a total of 532 articles, of which 25 met the inclusion criteria, corresponding to 26 reports. Although the approaches, methods and quality were heterogeneous among the included studies, 12 reported a negative correlation between AMS prevalence and age, 11 detected no relationship and three papers indicated that the age of AMS subjects was significantly higher than controls. Despite these differences, old age does not seem to be a contraindication for travelling at high altitude. Thus, the presented synthesis will be useful for health professionals in travel medicine to better tailor their appropriate care for older adults who travel to destinations at high altitude. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
29. Nepali earthquakes and the risk of an epidemic of hepatitis E.
- Author
-
Basnyat, Buddha, Dalton, Harry R., Kamar, Nassim, Rein, David B., Labrique, Alain, Farrar, Jeremy, and Piot, Peter
- Subjects
- *
EPIDEMICS , *HEPATITIS E - Abstract
A letter to the editor is presented about the risk of an epidemic of hepatitis E in Nepal following the earthquakes that hit the country in 2015.
- Published
- 2015
- Full Text
- View/download PDF
30. Pro: Pulse Oximetry Is Useful in Predicting Acute Mountain Sickness.
- Author
-
Basnyat, Buddha
- Subjects
- *
MOUNTAIN sickness , *PULSE oximeters , *NONINVASIVE diagnostic tests , *OXYHEMOGLOBIN , *BINDING sites , *HYPOXEMIA , *PARTIAL pressure - Published
- 2014
- Full Text
- View/download PDF
31. How can lessons from the COVID-19 pandemic enhance antimicrobial resistance surveillance and stewardship?
- Author
-
Walia, Kamini, Mendelson, Marc, Kang, Gagandeep, Venkatasubramanian, Ramasubramanian, Sinha, Rina, Vijay, Sonam, Veeraraghavan, Balaji, Basnyat, Buddha, Rodrigues, Camilla, Bansal, Nitin, Ray, Pallab, Mathur, Purva, Gopalakrishnan, Ram, and Ohri, Vinod C
- Subjects
- *
COVID-19 pandemic , *DRUG resistance in microorganisms , *MIDDLE-income countries , *LOW-income countries , *COMMUNITIES - Abstract
COVID-19 demanded urgent and immediate global attention, during which other public health crises such as antimicrobial resistance (AMR) increased silently, undermining patient safety and the life-saving ability of several antimicrobials. In 2019, WHO declared AMR a top ten global public health threat facing humanity, with misuse and overuse of antimicrobials as the main drivers in the development of antimicrobial-resistant pathogens. AMR is steadily on the rise, especially in low-income and middle-income countries across south Asia, South America, and Africa. Extraordinary circumstances often demand an extraordinary response as did the COVID-19 pandemic, underscoring the fragility of health systems across the world and forcing governments and global agencies to think creatively. The key strategies that helped to contain the increasing SARS-CoV-2 infections included a focus on centralised governance with localised implementation, evidence-based risk communication and community engagement, use of technological methods for tracking and accountability, extensive expansion of access to diagnostics, and a global adult vaccination programme. The extensive and indiscriminate use of antimicrobials to treat patients, particularly in the early phase of the pandemic, have adversely affected AMR stewardship practices. However, there were important lessons learnt during the pandemic, which can be leveraged to strengthen surveillance and stewardship, and revitalise efforts to address the AMR crisis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
32. Antibiotic resistance needs global solutions.
- Author
-
Basnyat, Buddha
- Published
- 2014
- Full Text
- View/download PDF
33. Detecting past and ongoing natural selection among ethnically Tibetan women at high altitude in Nepal.
- Author
-
Jeong, Choongwon, Witonsky, David B., Basnyat, Buddha, Neupane, Maniraj, Beall, Cynthia M., Childs, Geoff, Craig, Sienna R., Novembre, John, and Di Rienzo, Anna
- Subjects
- *
NATURAL selection , *BIOLOGICAL evolution , *BIOLOGICAL adaptation , *POPULATION genetics - Abstract
Adaptive evolution in humans has rarely been characterized for its whole set of components, i.e. selective pressure, adaptive phenotype, beneficial alleles and realized fitness differential. We combined approaches for detecting polygenic adaptations and for mapping the genetic bases of physiological and fertility phenotypes in approximately 1000 indigenous ethnically Tibetan women from Nepal, adapted to high altitude. The results of genome-wide association analyses and tests for polygenic adaptations showed evidence of positive selection for alleles associated with more pregnancies and live births and evidence of negative selection for those associated with higher offspring mortality. Lower hemoglobin level did not show clear evidence for polygenic adaptation, despite its strong association with an EPAS1 haplotype carrying selective sweep signals. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
34. Typhoid carriage in the gallbladder.
- Author
-
Basnyat, Buddha and Baker, Stephen
- Subjects
- *
SALMONELLA enterica serovar Typhi , *SYMPTOMS , *DIAGNOSIS , *GALLBLADDER , *IMMUNOFLUORESCENCE , *CARRIER state (Communicable diseases) , *CHOLECYSTECTOMY , *CHOLECYSTITIS , *SALMONELLA ,TYPHOID fever diagnosis - Abstract
The article describes the case of a male patient with Salmonella enterica serovar S Typhi. It discusses the symptoms shown by the patient upon admission to Patan Hospital in Kathmandu, Nepal, the patient's diagnosis, and examination of the patient's gallbladder with the use of immunofluorescent labelling.
- Published
- 2015
- Full Text
- View/download PDF
35. Tackle Nepal's typhoid problem now.
- Author
-
Basnyat, Buddha
- Subjects
- *
NEPAL Earthquake, 2015 , *EARTHQUAKES & society , *TYPHOID fever , *TYPHOID vaccines , *PREVENTION - Abstract
The article examines the earthquake that impacted the nation of Nepal in April 2015. Particular focus is given to how the post-earthquake conditions there are increasing the risk of a typhoid epidemic. Additional topics discussed include the typhoid vaccine, how some typhoid strains are becoming resistant to antibiotics and insights on the topic from the World Health Organization (WHO).
- Published
- 2015
- Full Text
- View/download PDF
36. A Diplomatic Disease.
- Author
-
Taylor, Ruthanne R., Basnyat, Buddha, and Scott, Robert McNair
- Subjects
- *
TRAVEL hygiene , *DIPLOMATS , *FOREIGN ministers (Cabinet officers) , *WOMEN diplomats , *MEDICAL care - Abstract
A 43-year-old diplomat was diagnosed with probable hepatitis C while vacationing in Europe. However, on return to her post in Nepal, she was actually found to have hepatitis E. The differential diagnosis, importance, and prevention of hepatitis E are highlighted. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
37. Clinical Features of Scrub Typhus.
- Author
-
Basnyat, Buddha, Belbase, Ram Hari, Zimmerman, Mark D., Woods, Christopher W., Reller, L. Barth, and Murdoch, David R.
- Subjects
- *
LETTERS to the editor , *TSUTSUGAMUSHI disease - Abstract
A letter to the editor in response to the article about the clinical features of scrub typhus appeared out of South and Southeast Asia is presented.
- Published
- 2006
- Full Text
- View/download PDF
38. Persistent Japanese Encephalitis in Kathmandu: The Need for Immunization.
- Author
-
Basnyat, Buddha, Zimmerman, Mark D., Shrestha, Yogesh, Scott, Robert McNair, and Endy, Timothy P.
- Subjects
- *
JAPANESE B encephalitis , *EPIDEMIC encephalitis - Abstract
Presents a study which examined the persistence of Japanese encephalitis (JE) in Kathmandu, Nepal. Methods; Results; Suggestion on the need for immunization to prevent the persistence of JE.
- Published
- 2001
39. Perspectives of pharmacy employees on an inappropriate use of antimicrobials in Kathmandu, Nepal.
- Author
-
Shrestha, Nistha, Manandhar, Sulochana, Maharjan, Nhukesh, Twati, Devina, Dongol, Sabina, Basnyat, Buddha, Baker, Stephen, and Karkey, Abhilasha
- Subjects
- *
EMPLOYEE attitudes , *ANTI-infective agents , *RESPIRATORY infections , *MIDDLE-income countries , *DRUGSTORES , *AZITHROMYCIN - Abstract
Background: Unregulated antimicrobial use is common in both hospital and community settings of low- and middle-income countries (LMICs). However, discrete data regarding the use/misuse of antimicrobials at pharmacies in LMICs are limited. This study was conducted to understand knowledge, attitude, and practice of pharmacy employees on antimicrobial dispensing in Nepal. Methods: We conducted a cross-sectional survey using a structured questionnaire on 801 pharmacy employees working in community and hospital pharmacies located in Lalitpur metropolitan city (LMC) of Kathmandu, Nepal between April 2017 and March 2019. Results: A majority (92%) of respondents agreed that demand for non-prescription antimicrobials was common. Asking for prescription before dispensing was ranked as the first preference by majority (69%) of participants. Suspected respiratory tract infection was the most common reason demanding for non-prescription antimicrobials with the highest mean rank of 1.5. Azithromycin was the most commonly prescribed and sold antimicrobial, as reported by 46% and 48% of participants respectively. A majority (87%) of respondents agreed on antimicrobial resistance (AMR) to be a global public health threat; and misuse/overuse of antimicrobials was perceived as the most common cause of AMR with a mean rank of 1.93. Conclusion: Our study revealed that unfounded dispensing and use of antimicrobials is prevalent among pharmacies in Kathmandu, Nepal. This over reliance on antimicrobials, notably azithromycin, may escalate burden of AMR. We identified several drivers of inappropriate antimicrobial dispensing practice in pharmacies, which will aid public health authorities in addressing these issues. Further studies considering role of other stakeholders, such as doctors, veterinarians, general public, and policy makers are required to obtain a more holistic perspectives on practices of antimicrobial use so to curb the extant AMR crisis. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
40. What Should We Be Recommending for the Treatment of Enteric Fever?
- Author
-
Parry, Christopher M, Qamar, Farah N, Rijal, Samita, McCann, Naina, Baker, Stephen, and Basnyat, Buddha
- Subjects
- *
TYPHOID fever , *SYMPTOMS , *DRUG resistance in microorganisms , *RANDOMIZED controlled trials , *MEROPENEM , *AZITHROMYCIN - Abstract
Patients with suspected enteric (typhoid and paratyphoid) fever are predominantly managed as outpatients in endemic regions. Nonspecific clinical presentation, lack of accurate diagnostic tools, and widespread antimicrobial resistance makes management challenging. Resistance has been described for all antimicrobials including chloramphenicol, amoxycillin, trimethoprim-sulfamethoxazole, ciprofloxacin, ceftriaxone, and azithromycin. No significant differences have been demonstrated between these antimicrobials in their ability to treat enteric fever in systematic reviews of randomized controlled trials (RCTs). Antimicrobial choice should be guided by local resistance patterns and national guidance. Extensively drug-resistant typhoid isolates require treatment with azithromycin and/or meropenem. Combining antimicrobials that target intracellular and extracellular typhoid bacteria is a strategy being explored in the Azithromycin and Cefixime in Typhoid Fever (ACT-SA) RCT, in progress in South Asia. Alternative antimicrobials, such as the oral carbapenem, tebipenem, need clinical evaluation. There is a paucity of evidence to guide the antimicrobial management of chronic fecal carriers. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
41. Advancing the evidence in altitude and wilderness medicine.
- Author
-
Zafren, Ken, Shlim, David R, Basnyat, Buddha, and Visser, Jenny
- Subjects
- *
MOUNTAINEERING , *MEDICINE , *MOUNTAIN sickness , *ALTITUDES - Published
- 2020
- Full Text
- View/download PDF
42. Rebuttal to the Con Statement.
- Author
-
Basnyat, Buddha
- Subjects
- *
MOUNTAIN sickness , *PULSE oximeters , *HYPOTHERMIA , *HYPOXEMIA , *GENETICS of disease susceptibility , *INFLUENCE of altitude - Published
- 2014
- Full Text
- View/download PDF
43. Antioxidant defense and oxidative damage vary widely among high-altitude residents.
- Author
-
Janocha, Allison J., Comhair, Suzy A. A., Basnyat, Buddha, Neupane, Maniraj, Gebremedhin, Amha, Khan, Anam, Ricci, Kristin S., Zhang, Renliang, Erzurum, Serpil C., and Beall, Cynthia M.
- Subjects
- *
PHYSIOLOGICAL effects of altitudes , *OXIDATIVE stress , *HYPOXEMIA , *PHYSIOLOGICAL effects of antioxidants , *DNA damage , *DEOXYGUANOSINE , *OROMO (African people) - Abstract
Objectives People living at high altitude experience unavoidable low oxygen levels (hypoxia). While acute hypoxia causes an increase in oxidative stress and damage despite higher antioxidant activity, the consequences of chronic hypoxia are poorly understood. The aim of the present study is to assess antioxidant activity and oxidative damage in high-altitude natives and upward migrants. Methods Individuals from two indigenous high-altitude populations (Amhara, n = 39), (Sherpa, n = 34), one multigenerational high-altitude population (Oromo, n = 42), one upward migrant population (Nepali, n = 12), and two low-altitude reference populations (Amhara, n = 29; Oromo, n = 18) provided plasma for measurement of superoxide dismutase (SOD) activity as a marker of antioxidant capacity, and urine for measurement of 8-hydroxy-2′-deoxyguanosine (8-OHdG) as a marker of DNA oxidative damage. Results High-altitude Amhara and Sherpa had the highest SOD activity, while highland Oromo and Nepalis had the lowest among high-altitude populations. High-altitude Amhara had the lowest DNA damage, Sherpa intermediate levels, and high-altitude Oromo had the highest. Conclusions High-altitude residence alone does not associate with high antioxidant defenses; residence length appears to be influential. The single-generation upward migrant sample had the lowest defense and nearly the highest DNA damage. The two high-altitude resident samples with millennia of residence had higher defenses than the two with multiple or single generations of residence. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
44. Letter: Is Altitude-Induced Sleep Apnea Highly Dependent on Ethnic Background (Sherpa vs. Tamang)? We Are Not Convinced. (re: doi: 10.1089/ham.2022.0012).
- Author
-
Zafren, Ken, Pun, Matiram, and Basnyat, Buddha
- Subjects
- *
SLEEP apnea syndromes , *ETHNICITY - Abstract
We are also concerned that the study may not have been approved by the Nepal Health Research Council (NHRC), the organization by which all human subjects research in Nepal must be approved. For studies by foreign researchers, the NHRC usually recommends that a Nepali health professional serve as a coprincipal investigator so that the foreign team members can receive adequate professional help to carry out the study in Nepal. Letter: Is Altitude-Induced Sleep Apnea Highly Dependent on Ethnic Background (Sherpa vs. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF
45. Acute high-altitude illnesses.
- Author
-
Basnyat, Buddha
- Published
- 2013
- Full Text
- View/download PDF
46. A longitudinal cline characterizes the genetic structure of human populations in the Tibetan plateau.
- Author
-
Jeong, Choongwon, Peter, Benjamin M., Basnyat, Buddha, Neupane, Maniraj, Beall, Cynthia M., Childs, Geoff, Craig, Sienna R., Novembre, John, and Di Rienzo, Anna
- Subjects
- *
HUMAN genetic variation , *INDIGENOUS peoples , *GENE flow , *GENETIC markers - Abstract
Indigenous populations of the Tibetan plateau have attracted much attention for their good performance at extreme high altitude. Most genetic studies of Tibetan adaptations have used genetic variation data at the genome scale, while genetic inferences about their demography and population structure are largely based on uniparental markers. To provide genome-wide information on population structure, we analyzed new and published data of 338 individuals from indigenous populations across the plateau in conjunction with worldwide genetic variation data. We found a clear signal of genetic stratification across the east-west axis within Tibetan samples. Samples from more eastern locations tend to have higher genetic affinity with lowland East Asians, which can be explained by more gene flow from lowland East Asia onto the plateau. Our findings corroborate a previous report of admixture signals in Tibetans, which were based on a subset of the samples analyzed here, but add evidence for isolation by distance in a broader geospatial context. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
47. Association of Pre-existing Mental Health Conditions with Acute Mountain Sickness at Everest Base Camp.
- Author
-
Hüfner, Katharina, Caramazza, Fabio, Pircher Nöckler, Evelyn R., Stawinoga, Agnieszka E., Fusar-Poli, Paolo, Bhandari, Sanjeeb S., Basnyat, Buddha, Brodmann Maeder, Monika, Strapazzon, Giacomo, Tomazin, Iztok, Zafren, Ken, Brugger, Hermann, and Sperner-Unterweger, Barbara
- Subjects
- *
MOUNTAIN sickness , *MENTAL health , *MENTAL illness , *ASSOCIATION of ideas , *DRUG abuse - Abstract
Hüfner, Katharina, Fabio Caramazza, Evelyn R. Pircher Nöckler, Agnieszka E. Stawinoga, Paolo Fusar-Poli, Sanjeeb S. Bhandari, Buddha Basnyat, Monika Brodmann Maeder, Giacomo Strapazzon, Iztok Tomazin, Ken Zafren, Hermann Brugger, and Barbara Sperner-Unterweger. Association of pre-existing mental health conditions with acute mountain sickness at Everest Base Camp. High Alt Med Biol. 23:338–344, 2022. Background: Mental health disorders are common, but limited data are available regarding the number of people with a past medical history of psychiatric diagnoses going to high altitude (HA). It is also unknown whether mental health conditions are associated with an increased risk of acute mountain sickness (AMS). Methods: We analyzed data from a previous study at Everest Base Camp. Participants self-reported their past medical history and history of substance use and had a brief history taken by a physician. AMS was assessed using the self-reported 2018 Lake Louise AMS Score. Results: Eighty-five participants (66 men and 19 women, age 38 ± 9 years) were included. When questioned by a physician, 28 participants reported prior diagnoses or symptoms compatible with depression (23%), anxiety disorder (6%), post-traumatic stress disorder (1%), and psychosis/psychotic experiences (9%). The prevalence of psychiatric diagnoses in the past medical history was much lower in the self-reported data (2/85) compared to data obtained via physician assessment (28/85). Increased risks of AMS were associated with a past medical history of anxiety disorder (odds ratio [OR] 22.7; confidence interval [95% CI] 2.3–220.6; p < 0.001), depression (OR 3.6; 95% CI 1.2–11.2; p = 0.022), and recreational drug use ever (OR 7.3; 95% CI 1.5–35.5; p = 0.006). Conclusions: Many people who travel to HA have a past medical history of mental health conditions. These individuals have an increased risk of scoring positive for AMS on the Lake Louise Score compared with people without a history of mental health conditions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
48. Neglected hepatitis E and typhoid vaccines.
- Author
-
Basnyat, Buddha
- Subjects
- *
LETTERS to the editor , *HEPATITIS E , *VACCINATION - Abstract
A letter to the editor is presented in response to the article "Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomized, double-blind placebo-controlled, phase 3 trial," by Feng-Cai Zhu and colleagues, published in the September 11, 2010 issue.
- Published
- 2010
- Full Text
- View/download PDF
49. Typhoid Fever in the United States and Antibiotic Choice.
- Author
-
Basnyat, Buddha
- Subjects
- *
LETTERS to the editor , *TYPHOID fever - Abstract
A letter to the editor is presented in response to the article "Typhoid Fever in the United States, 1999-2006," by M. F. Lynch and colleagues published in a 2009 issue.
- Published
- 2010
- Full Text
- View/download PDF
50. Reducing the Incidence of High-Altitude Pulmonary Edema.
- Author
-
Basnyat, Buddha
- Subjects
- *
LETTERS to the editor , *PULMONARY edema - Abstract
A letter to the editor is presented in response to the study "Both Tadalafil and Dexamethasone May Reduce the Incidence of High-altitude Pulmonary Edema," by M. Maggiorini and colleagues in the 2006 issue.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.